scholarly journals Sexual side-effects of antidepressant and antipsychotic drugs

2003 ◽  
Vol 9 (3) ◽  
pp. 202-210 ◽  
Author(s):  
David Baldwin ◽  
Andrew Mayers
Keyword(s):  
Side Effects ◽  
Sexual Dysfunction ◽  
Adverse Effects ◽  
Sexual Function ◽  
Psychotropic Drugs ◽  
Antipsychotic Drugs ◽  
Well Being ◽  
Sexual Expression ◽  
Human Relationships ◽  
Sexual Side Effects

Adequate sexual expression is essential to many human relationships and provides a sense of physical, psychological and social well-being. Epidemiological and clinical studies show that depression and schizophrenia are associated with impairment of sexual function and satisfaction, even in untreated patients. Most antidepressant and antipsychotic drugs have adverse sexual effects but it is difficult accurately to identify the incidence of treatment-emergent dysfunction, as disturbances can be reliably detected only from systematic enquiries made at baseline and during treatment. Growing awareness of the adverse effects of psychotropic drugs has led to attempts to use adjuvants or substitute treatments to resolve sexual dysfunction. More studies of the effects of antidepressant and antipsychotic drugs on sexual function are needed.

Sexual Dysfunction in Patients with Neuropsychiatric Disorders: Challenges and Opportunities

CNS Spectrums ◽  
2006 ◽  
Vol 11 (S9) ◽  
pp. 4-4
Author(s):  
Barry Gidal ◽  
John J. Barry
Keyword(s):  
Quality Of Life ◽  
Sexual Dysfunction ◽  
Adverse Effects ◽  
Sexual Function ◽  
Healthcare Providers ◽  
Well Being ◽  
Sexual Disorders ◽  
Functional Impairments ◽  
The Impact

Quality-of-life issues in healthcare have come to be of paramount importance for a population that increasingly expects healthcare not only to treat major illnesses but also to optimize normal levels of physical and psychosocial functioning and overall well-being. Healthcare providers have also increasingly appreciated the impact that adverse effects of treatment can have on quality of life, as well as on compliance with and the effectiveness of treatment.Many functional impairments and adverse treatment effects take the form of clinical complaints that patients and caregivers typically report to their healthcare providers without prompting. Other adverse effects are not so obviously clinical or treatment-related, and patients may not be inclined or may even be reluctant to bring them up when talking with the provider. Impairment of sexual function is a problem of this kind.Sexual dysfunction appears to be common and frequently underrecognized in certain patient populations. For example, it has been estimated that 25% to 63% of women and 10% to 52% of men with epilepsy have some form of sexual dysfunction, yet in clinical reviews of sexual disorders, epilepsy is not listed as one of the medical conditions commonly associated with impaired sexual function.

Female Sexual Side Effects Associated with Selective Serotonin Reuptake Inhibitors: A Descriptive Clinical Study of 33 Patients

1995 ◽  
Vol 25 (3) ◽  
pp. 239-248 ◽  
Author(s):  
Winston W. Shen ◽  
Jeffrey H. Hsu
Keyword(s):  
Side Effects ◽  
Sexual Dysfunction ◽  
Adverse Effects ◽  
Serotonin Reuptake ◽  
Female Sexual Dysfunction ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Spontaneous Remission ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Sexual Side Effects

Objective: After the advent of selective serotonin reuptake inhibitors on the U.S. market in 1988, American psychiatrists have been faced with more choices of antidepressants for the treatment of depression. The prescribing of SSRIs has been increasing in popularity because they are easily titrated by the physicians and tolerated by patients. However, the SSRI use is frequently associated with female sexual dysfunction. The aim of this study was to describe these SSRI-associated female sexual side effects. Methods: In a retrospective series, clinic records of 110 female SSRI-treated outpatients were reviewed for loss of or decreased libido, orgasmic disturbances (anorgasmia or delayed orgasm), as well as clinical management patterns to alleviate sexual side effects. Results: Twenty-one fluoxetine-, nine paroxetine-, and five sertraline-treated cases with female sexual inhibition were identified. The fates of SSRI-associated sexual adverse effects and clinical managements of restoring these side effects were described. Conclusions: With some limitations in interpreting the data, the findings of this study suggest that SSRI-associated female sexual dysfunction occurs at a higher rate than we previously thought, equal potentials in implicating female sexual side effects among three SSRIs, and the absence or the low incidence of female sexual adverse effects from bupropion, and that these side effects can be managed by waiting for a spontaneous remission, dosage reduction of SSRIs, substitution with bupropion and other antidepressants, or the use of an antidote.

Sexual Side-Effects of Contemporary Antidepressants: Review

2009 ◽  
Vol 43 (9) ◽  
pp. 795-808 ◽  
Author(s):  
Isaac Schweitzer ◽  
Kay Maguire ◽  
Chee Ng
Keyword(s):  
Major Depressive Disorder ◽  
Side Effects ◽  
Sexual Dysfunction ◽  
Depressive Disorder ◽  
Sexual Function ◽  
Rating Scales ◽  
Major Depressive ◽  
Double Blind ◽  
Direct Assessment ◽  
Sexual Side Effects

The aim of the present study was to review the sexual side-effects of contemporary antidepressants in Australia, comparing the selective serotonin re-uptake inhibitors (SSRIs) with venlafaxine, reboxetine, mirtazepine, duloxetine, bupropion, desvenlafaxine and agomelatine. Double-blind, randomized comparative studies of these antidepressants that included assessment of sexual dysfunction with validated rating scales in patients with major depressive disorder were identified from the literature using MEDLINE, EMBASE and PsychINFO databases. Bupropion and duloxetine caused significantly less sexual dysfunction than the SSRIs in short-term studies and reboxetine significantly less in both short- and longer term studies. Bupropion and agomelatine caused significantly less sexual dysfunction than venlafaxine. The evidence for mirtazepine having an advantage over the SSRIs is lacking and there are currently insufficient data for desvenlafaxine. Well-designed comparative studies of contemporary antidepressants with direct assessment of sexual side-effects as the primary outcome measure are scarce. Future studies should be randomized, double-blind, active controlled trials in sexually active subjects with major depressive disorder. There should be direct assessment of sexual function and depression using reliable, validated rating scales before and during treatment. Studies should assess treatment-emergent effects in patients with normal function and resolution of baseline dysfunction over treatment, in both the short and long term. Further research should compare available instruments for measuring sexual function, and include separate analyses of both remitters/non-remitters and male/female subjects.

Sexual side effects in patients treated with desvenlafaxine: An observational study in daily practice

2016 ◽  
Vol 33 (S1) ◽  
pp. s227-s228 ◽  
Author(s):  
B. Navarro ◽  
L. Perez ◽  
L. Erkoreka ◽  
A. Arroita ◽  
I. Perez
Keyword(s):  
Side Effects ◽  
Sexual Dysfunction ◽  
Side Effect ◽  
Daily Practice ◽  
Well Being ◽  
Common Side Effect ◽  
Sexual Side Effects ◽  
Health Centres ◽  
Competing Interest ◽  
Orgasmic Dysfunction

IntroductionSexual function is important for patients’ well-being but it is a common side effect of SSRI and SNRI, included desvenlafaxine.Objectives and aimsEvaluate incidence and characteristics of sexual dysfunction caused by desvenlafaxine in the clinical practice.MethodsOne hundred and thirty-three patients with recently introduced desvenlafaxine treatment are recruited from Barakldo and Uribe-Kosta Mental Health Centres in Biscay, Spain. UKU scale is administered to measure sexual side effects. Statistical analysis is performed using SPSS v.22.ResultsSexual dysfunction is observed in 5 patients (3.7%) at 50 and 100 mg/d (2 and 3 patients, respectively) desvenlafaxine doses. Two patients (1.5%) have experimented more than one sexual side effect. Regarding gender differences, the most frequent sexual dysfunctions are diminished sexual desire (5.5%) and erectile dysfunction (5.5%) in men and orgasmic dysfunction (1.2%) in women (P-values are 0.034; 0.034 and 0.408, respectively). Discontinuation is decided in 60% of patients.ConclusionsDesvenlafaxine has a well-tolerated sexual side effect profile in general population. There are some gender-related differences both in presentation and perception, as it has been described with other drugs, and this should be taken into account by prescriptors.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Post-treatment physiological effects, adverse effects and complications after the selected aesthetic treatments. Review of the literature

2021 ◽  
Vol 10 (5) ◽  
pp. 211-216
Author(s):  
Weronika S. Kononowicz ◽  
◽  
Beata Malara ◽  
Keyword(s):  
Side Effects ◽  
Adverse Effects ◽  
Physical Attractiveness ◽  
Treatment Effects ◽  
Well Being ◽  
Post Treatment ◽  
Physiological Effects ◽  
Review Of The Literature ◽  
Skin Defects

Aesthetic treatments are performed in order to improve physical attractiveness, well-being, and to eliminate skin defects. These procedures are also associated with physiological post-treatment effects, side effects and complications. The aim of the article was to discuss selected aesthetic treatments with their typical complications and to present the types of natural post-treatment effects and dangerous side effects. Knowledge of the causes and occurrence of undesirable effects after various aesthetic treatments allows to increase awareness of the risks associated with the performance of such procedures.

Monoamine Agonists (“Antidepressants”), Including Dopamine Agonists (“Stimulants”)

2018 ◽  
pp. 85-100
Author(s):  
S. Nassir Ghaemi
Keyword(s):  
Clinical Pharmacology ◽  
Side Effects ◽  
Sexual Dysfunction ◽  
Drug Interactions ◽  
Psychotropic Drugs ◽  
Withdrawal Syndrome ◽  
Serotonin Reuptake ◽  
Dopamine Agonists ◽  
Serotonin Reuptake Inhibitors ◽  
Norepinephrine Reuptake

The drug class of monoamine agonists includes agents called antidepressants and stimulants. Monoamine agonists are the most widely used class of psychotropic drugs. There are three major monoamines, and thus three main types of monoamine agonists. We consider each in turn: the serotonin reuptake inhibitors (SRIs), norepinephrine reuptake inhibitors (NRIs), and dopaminergic agents. We also discuss the dopamine agonists—bupropion (Wellbutrin) and amphetamines (“stimulants”), as well as other new monoamine agonists. The clinical pharmacology of specific agents within each class, including their efficacy and side effects, is explored. Specific phenomena surveyed include SRI tolerance, sexual dysfunction, drug interactions, serotonin withdrawal syndrome, and suicide and akathisia.

Sexual Dysfunction

2014 ◽  
pp. 97-98
Author(s):  
David L Brody
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Drug Abuse ◽  
Side Effects ◽  
Sexual Dysfunction ◽  
Pde5 Inhibitor ◽  
Cauda Equina ◽  
Sexual Side Effects ◽  
Severe Fatigue ◽  
Cord Injury

This chapter addresses issues surrounding sexual dysfunction after concussion. Ask the patient specifically about sexual dysfunction in private, and if appropriate ask the collateral source separately. Assess for depression, severe fatigue or hypersomnia, untreated pain, and alcohol or drug abuse (especially marijuana). Check medications for sexual side effects; serotonin specific reuptake inhibitors are the most common culprits. Test for hormonal imbalances and unrecognized cauda equina or lower spinal cord injury. Consider a trial of a PDE5 inhibitor and refer to urology for more advanced options.

scholarly journals MEDICINAL HERBS AND PHYTOCHEMICALS USED IN THE TREATMENT OF DEPRESSION: A REVIEW

2019 ◽  
pp. 8-14
Author(s):  
APOORVA HA ◽  
SEEMA MEHDI ◽  
KRISHNA KL ◽  
NABEEL K
Keyword(s):  
Side Effects ◽  
Adverse Effects ◽  
Clinical Evidence ◽  
Emotional State ◽  
Well Being ◽  
New Approach ◽  
Treatment Of Depression ◽  
Primary Hypothesis ◽  
The Brain ◽  
Additional Option

Depression is a condition of no mood and loss of interest in any activity that can diminish a person’s thinking, conduct, tendencies, emotional state, and a sense of well-being. Although there is a conventional class of medication which have been beneficial in the treatment of depression, current studies have reported having side effects which can be minimized by the intervention of herbs and phytochemicals. Most of the studies have proven the various mechanisms and have started to research a very ground-breaking method by glancing the ancient treatmen. Where this new approach of using the herbs and phytochemicals has shown better results alone and in combination with conventional drugs which has shown lesser adverse effects. The practice of phytomedicine is an additional option for the treatment of depression. In the various segments of treating the depression, the mainstream can be a breakthrough including phytoconstituents. In this aspect, there are many contributions for the treatment of the depression acting to the neuronal level signaling and the phytoconstituents also have shown some basic mechanisms in the treatment of depression as that of the conventional medications following some primary hypothesis and signaling pathways and life interactions that effects the brain in either way to treat the depression in all sort of way. Clinical evidence is required to provide backing to the safety and effectiveness of herbs and phytochemicals alone or in combination with currently available drugs to overcome the reported side effects during the treatment of depression.

Secondary sexual dysfunction with antidepressant treatment: Study on 50 patients

2016 ◽  
Vol 33 (S1) ◽  
pp. S591-S591
Author(s):  
O.W. Muquebil Ali Al Shaban Rodriguez ◽  
S. Ocio León ◽  
M. Gómez Simón ◽  
M.J. Hernández González ◽  
E. Álvarez de Morales Gómez-Moreno ◽  
...  
Keyword(s):  
Side Effects ◽  
Sexual Dysfunction ◽  
Treatment Adherence ◽  
Antidepressant Treatment ◽  
Antidepressant Drugs ◽  
Sexual Side Effects ◽  
Competing Interest ◽  
The Relationship ◽  
Transversal Study

IntroductionThe side effects of the various antidepressant drugs on the sexual field (with very few exceptions) are well known, and they affect the quality of life in important manners. The incidence rate, communicated spontaneously by the patient, has been estimated around 10–15%, and can reach amounts of 50–60% with SSRIs when studied specifically. It has been suggested that these effects compromise treatment adherence.ObjectivesTo estimate the incidence and intensity of the side effects on the sexual field with different antidepressants, as well as its relationship with treatment adherence.MethodologyTransversal study on 50 patients assisted in medical consultation. Collection of data in office (October 2014–October 2015).Administration of survey PRSexDQ-SALSEX. In order to research the relationship with treatment adherence, one question surveyed the patient whether he/she had thought about finishing treatment for this reason.ResultsTwenty-nine patients (58% of the sample) presented some degree of sexual dysfunction. Five individuals (17.2%) communicated it spontaneously. Nine individuals (31%) responded that they did not accept positively the changes in their sexual field, and they had thought about withdrawing treatment for this reason. They were given the test of self-compliance statement (Haynes-Sackett), with a result of four non-compliant (44.4%). The most frequently involved drugs were fluoxetine (n = 5, 10% of the sample total) and paroxetine (n = 4, 8%).ConclusionsThe high impact of sexual side effects with a low rate of spontaneous communication coincides with previous existent studies.Limitation when estimating adhesion due to methodological difficulties in the design of the study. However, high impression by using the selected method of determination.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Increased libido as a buproion-SR side effect: Clinical description of a case

2016 ◽  
Vol 33 (S1) ◽  
pp. S545-S545 ◽  
Author(s):  
L. Gallardo Borge ◽  
C. Noval Canga ◽  
L. Rodíguez Andrés ◽  
I. Sevillano Benito ◽  
M. Hernández García ◽  
...  
Keyword(s):  
Side Effects ◽  
Sexual Dysfunction ◽  
Side Effect ◽  
Muscle Tension ◽  
Negative Influence ◽  
Sexual Life ◽  
Clinical Report ◽  
Consultation Room ◽  
Sexual Side Effects ◽  
History Of

IntroductionBupropion is a dual antidepressant, a norepinephrine and dopamine reuptake inhibitor. Its main use is in affective disorders as major depression. Antidepressants have been commonly associated with sexual side effects in the libido, sexual arousal, orgasm and erectile function. Bupropion has negative influence in sexual function, even it could increase the libido. Due to this, it could be a good option in patients with active sexual life and affective disorder.Clinical reportA 58-year-old female with a long history of depression disorder for 5 years. History of lots of side effects with different treatments, sexual dysfunction with serotonin-antidepressants. Treated with bupropion SR 150 mg/day and alprazolam, she suffered a relapse. The bupropion was increased to 300 mg/day. Three days later she appeared in the consultation room, presented a sense of pre-orgasmic of 72 hours of evolution, high increased libido, tiredness, muscle tension and insomnia. This sense did not improve after the sexual act. It had never happened previously. The side effect improved when the bupropion was reduced to 150 mg/day and disappeared with its withdrawal.ConclusionsThe case made a relationship between the increased of bupropion's dose and the appearance of unusual sexual side effects (increased of libido and pre-orgasmic sense). Not only bupropion is one of the antidepressants that do not cause sexual dysfunction, if not it was reported in some trials that could be a treatment against this dysfunction due to its prosexual effects. The mechanism is unknown but could be related with norepinephrine or dopamine transmission.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Sign in / Sign up

Export Citation Format

Share Document